$NTRA

Sheena Jonathan sold $330K of NTRA (indirect holdings)

Sheena Jonathan sold 1,500 indirectly-held shares of Natera, Inc. (NTRA) at an average of $219.87 ($218.14–$222.14, $0.33M total) across 9 trades on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Jun 23, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 23, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount ($329,809.76) and that it was executed under a pre-arranged Rule 10b5-1 plan; no other company-specific developments are provided.

02

Market read

Primarily a sentiment/positioning datapoint for NTRA; not a fundamental catalyst by itself.

03

What to watch

The filing is indirect holdings and multi-trade execution; without context on total insider activity or remaining plan size, directional inference is limited.

Relevance 3/10Novelty 3/10Timing: after-hours/filing update (Form 4 filed 2026-06-22 for trades dated 2026-06-17)

Background

The article is a SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold about $329.8K of NTRA shares via an open-market sale under a 10b5-1 plan on 2026-06-17.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless paired with other new fundamentals.

Evidence & confidence

This is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and no accompanying company-specific news (earnings, guidance, deal, or regulatory action).

Market effects

Minimal; single-company insider sale without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may not reflect bearish expectations; traders may discount it entirely.

Key entities

  • Natera, Inc.

    Issuer of the Form 4 insider transaction; director Sheena Jonathan sold shares under a 10b5-1 plan.

  • Sheena Jonathan

    Director reporting an indirect open-market sale of 1,500 shares across nine trades.

Related articles

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.